# Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

> **NCT06705686** · PHASE1 · RECRUITING · sponsor: **TechnoGenesys, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (CRPC)
- Metastatic Castration-resistant Prostate Carcinoma

## Interventions

- **DRUG:** (R)-9bMS

## Key facts

- **NCT ID:** NCT06705686
- **Lead sponsor:** TechnoGenesys, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705686, "Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06705686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*